Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Replication stress response in cancer stem cells as a target for chemotherapy.

Manic G, Sistigu A, Corradi F, Musella M, De Maria R, Vitale I.

Semin Cancer Biol. 2018 Aug 3. pii: S1044-579X(18)30019-1. doi: 10.1016/j.semcancer.2018.08.003. [Epub ahead of print] Review.

PMID:
30081229
2.

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Aricò E.

Cancer Immunol Res. 2018 Jun;6(6):658-670. doi: 10.1158/2326-6066.CIR-17-0675. Epub 2018 Apr 5.

PMID:
29622580
3.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

4.

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G.

Immunol Rev. 2017 Nov;280(1):165-174. doi: 10.1111/imr.12582. Review.

PMID:
29027230
5.

The added value of type I interferons to cytotoxic treatments of cancer.

Bracci L, Sistigu A, Proietti E, Moschella F.

Cytokine Growth Factor Rev. 2017 Aug;36:89-97. doi: 10.1016/j.cytogfr.2017.06.008. Epub 2017 Jun 19. Review.

PMID:
28693974
6.

IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils.

Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F, Buccione C, Sistigu A, Sanchez M, Andreone S, D'Urso MT, Spada M, Macchia D, Afferni C, Mattei F, Schiavoni G.

Oncoimmunology. 2017 Apr 20;6(6):e1317420. doi: 10.1080/2162402X.2017.1317420. eCollection 2017.

7.

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Musella M, Manic G, De Maria R, Vitale I, Sistigu A.

Oncoimmunology. 2017 Apr 5;6(5):e1314424. doi: 10.1080/2162402X.2017.1314424. eCollection 2017. Review.

8.

Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting.

Sistigu A, Di Modugno F, Manic G, Nisticò P.

Cytokine Growth Factor Rev. 2017 Aug;36:67-77. doi: 10.1016/j.cytogfr.2017.05.008. Epub 2017 May 31. Review.

9.

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, Musella M, Vitale S, De Angelis ML, Pallocca M, Amoreo CA, Sperati F, Di Franco S, Barresi S, Policicchio E, De Luca G, De Nicola F, Mottolese M, Zeuner A, Fanciulli M, Stassi G, Maugeri-Saccà M, Baiocchi M, Tartaglia M, Vitale I, De Maria R.

Gut. 2018 May;67(5):903-917. doi: 10.1136/gutjnl-2016-312623. Epub 2017 Apr 7.

10.

Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases.

Manic G, Corradi F, Sistigu A, Siteni S, Vitale I.

Int Rev Cell Mol Biol. 2017;328:105-161. doi: 10.1016/bs.ircmb.2016.08.004. Epub 2016 Oct 18. Review.

PMID:
28069132
11.

Trial watch - inhibiting PARP enzymes for anticancer therapy.

Sistigu A, Manic G, Obrist F, Vitale I.

Mol Cell Oncol. 2015 Jun 10;3(2):e1053594. doi: 10.1080/23723556.2015.1053594. eCollection 2016 Mar. Review.

12.

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Manic G, Obrist F, Sistigu A, Vitale I.

Mol Cell Oncol. 2015 Feb 23;2(4):e1012976. doi: 10.1080/23723556.2015.1012976. eCollection 2015 Oct-Dec. Review.

13.

LTX-315, CAPtivating immunity with necrosis.

Sistigu A, Manic G, Vitale I.

Cell Cycle. 2016 May 2;15(9):1176-7. doi: 10.1080/15384101.2016.1160609. Epub 2016 Mar 17. No abstract available.

14.

Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.

Jemaà M, Manic G, Lledo G, Lissa D, Reynes C, Morin N, Chibon F, Sistigu A, Castedo M, Vitale I, Kroemer G, Abrieu A.

Oncotarget. 2016 Jan 5;7(1):885-901. doi: 10.18632/oncotarget.6432.

15.

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G.

Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.

16.

Autocrine signaling of type 1 interferons in successful anticancer chemotherapy.

Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L, Kroemer G.

Oncoimmunology. 2015 Jul 25;4(8):e988042. eCollection 2015 Aug.

17.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

18.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
19.

A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells.

Mattei F, Schiavoni G, De Ninno A, Lucarini V, Sestili P, Sistigu A, Fragale A, Sanchez M, Spada M, Gerardino A, Belardelli F, Businaro L, Gabriele L.

J Immunotoxicol. 2014 Oct;11(4):337-46. doi: 10.3109/1547691X.2014.891677. Epub 2014 Mar 6.

PMID:
24597645
20.

CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G.

Cancer Res. 2014 Jan 15;74(2):436-45. doi: 10.1158/0008-5472.CAN-13-1265. Epub 2013 Dec 3.

21.

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.

Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, Galanos C, André F, Kroemer G, Zitvogel L.

Cell Death Differ. 2014 Jan;21(1):69-78. doi: 10.1038/cdd.2013.72. Epub 2013 Jun 28.

22.

Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.

Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G.

Cell Death Differ. 2014 Jan;21(1):59-68. doi: 10.1038/cdd.2013.73. Epub 2013 Jun 21.

23.

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Bracci L, Schiavoni G, Sistigu A, Belardelli F.

Cell Death Differ. 2014 Jan;21(1):15-25. doi: 10.1038/cdd.2013.67. Epub 2013 Jun 21. Review.

24.

IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.

Mattei F, Schiavoni G, Sestili P, Spadaro F, Fragale A, Sistigu A, Lucarini V, Spada M, Sanchez M, Scala S, Battistini A, Belardelli F, Gabriele L.

Neoplasia. 2012 Dec;14(12):1223-35.

25.

An immunosurveillance mechanism controls cancer cell ploidy.

Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, Shen S, Mariño G, Criollo A, Boilève A, Job B, Ladoire S, Ghiringhelli F, Sistigu A, Yamazaki T, Rello-Varona S, Locher C, Poirier-Colame V, Talbot M, Valent A, Berardinelli F, Antoccia A, Ciccosanti F, Fimia GM, Piacentini M, Fueyo A, Messina NL, Li M, Chan CJ, Sigl V, Pourcher G, Ruckenstuhl C, Carmona-Gutierrez D, Lazar V, Penninger JM, Madeo F, López-Otín C, Smyth MJ, Zitvogel L, Castedo M, Kroemer G.

Science. 2012 Sep 28;337(6102):1678-84.

PMID:
23019653
26.

Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy.

Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, Zitvogel L.

Cancer J. 2011 Sep-Oct;17(5):351-8. doi: 10.1097/PPO.0b013e3182325d4d. Review.

PMID:
21952286
27.

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.

Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L.

Semin Immunopathol. 2011 Jul;33(4):369-83. doi: 10.1007/s00281-011-0245-0. Epub 2011 May 25. Review.

PMID:
21611872
28.

Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.

Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G.

J Immunol. 2011 May 1;186(9):5142-50. doi: 10.4049/jimmunol.1004163. Epub 2011 Mar 25.

29.

Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells.

Sistigu A, Bracci L, Valentini M, Proietti E, Bona R, Negri DR, Ciccaglione AR, Tritarelli E, Nisini R, Equestre M, Costantino A, Marcantonio C, Santini SM, Lapenta C, Donati S, Tataseo P, Miceli M, Cara A, Federico M.

Vaccine. 2011 Apr 18;29(18):3465-75. doi: 10.1016/j.vaccine.2011.02.059. Epub 2011 Mar 5.

PMID:
21382480
30.

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis.

Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L.

Cancer Res. 2011 Feb 1;71(3):768-78. doi: 10.1158/0008-5472.CAN-10-2788. Epub 2010 Dec 13.

31.

Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells.

Muratori C, Ruggiero E, Sistigu A, Bona R, Federico M.

J Gen Virol. 2009 Nov;90(Pt 11):2777-87. doi: 10.1099/vir.0.012609-0. Epub 2009 Jul 22.

PMID:
19625465
32.

Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9.

Muratori C, Sistigu A, Ruggiero E, Falchi M, Bacigalupo I, Palladino C, Toschi E, Federico M.

J Virol. 2007 Sep;81(17):9078-87. Epub 2007 Jun 20.

Supplemental Content

Loading ...
Support Center